Literature DB >> 19761136

Analysis of the results and long-term follow-up of second-look laparotomy in advanced ovarian cancer.

S Sawicki1, D Wydra, J Kobierski, T Milczek, J Emerich.   

Abstract

OBJECTIVE: The goal of the study was to analyze results of 171 second-look laparotomy and compare survival of patients with advanced ovarian cancer depending on SLL results.
RESULTS: We obtained the following results: complete pathologic response (CPR)--56.2% (96 patients), microscopic disease (R(micro))--12.8% (22 patients), macroscopic disease (R(marco))--31% (53 patients). In patients with negative SLL results disease recurrence was diagnosed in 38.5%. We compared survival in separate groups of patients depending on SLL results: no difference between the CPR group and R(micro) group. Significantly longer survival of patients in the R(micro) group was found compared to patients with recurrence after negative SLL. There were no differences between the group with recurrence after negative SLL and the R(macro) group.
CONCLUSIONS: An important observation is that the survival rate in patients with recurrence after negative SLL was significantly lower compared to patients with microscopic disease. The probable explanation for favorable prognosis in the group with microscopic disease was early administration of chemotherapy after SLL.

Entities:  

Mesh:

Year:  2009        PMID: 19761136

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  2 in total

1.  Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.

Authors:  Xia Xu; Yan Wang; Fang Wang; Lizhou Jia; Yiqin Zhou; Fei Deng; Junwei Qu; Bifang Zhou; Aifeng Meng; Bole Fu; Xiaoxiang Chen; Zhiying Qian; Jinhua Wang
Journal:  J Ovarian Res       Date:  2013-04-25       Impact factor: 4.234

2.  Results of second-look laparotomy in advanced ovarian cancer: one single center experience.

Authors:  Tarak Damak; Riadh Chargui; Jamel Ben Hassouna; Monia Hechiche; Khaled Rahal
Journal:  ISRN Obstet Gynecol       Date:  2012-10-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.